N/A
N=102
Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis
Perforated Appendicitis
Bottom Line
View on ClinicalTrials.gov: NCT00462020 ↗Enrolled (actual)
102
Serious AEs
0.0%
Results posted
Dec 2011
Primary outcome: Primary: Abscess After Appendectomy — 10; 10 number of patients
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- 5 days of IV antibiotics (ceftriaxone and metronidazole) (Drug); Home with oral antibiotics when eating (ampicillin/clavulanic acid) (Drug)
- Age
- Pediatric, Adult
- Sex
- All
- Sponsor
- Children's Mercy Hospital Kansas City
- Primary completion
- Nov 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Abscess After Appendectomy |
10; 10 | — |
| SECONDARY Operative Time |
41.06; 46.30 | — |
| SECONDARY Time to Regular Diet |
68.00; 61.42 | — |
| SECONDARY Length of Stay After Operation |
6.06; 4.48 | — |
| SECONDARY Total Healthcare Visits |
3.1; 3.1 | — |
Summary
The objective of this study is to scientifically evaluate two different management strategies for perforated appendicitis.
The hypothesis is that early discharge with oral antibiotic therapy may result in a dramatic decrease in medical care expenses for the patient.
The primary outcome variable between the two strategies is abscess rate.
Eligibility Criteria
Inclusion Criteria
- Identifiable hole in the appendix or stool in the abdomen at the time of appendectomy
Exclusion Criteria
- Known immune deficiency
- Abscess identified on pre-op imaging
- Another condition affecting surgical decision making or recovery (e.g. hemophilia, severe cardiac or respiratory co-morbidities).
Data sourced from ClinicalTrials.gov (NCT00462020). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.